Categories: News

Option Care Health Reports Financial Results for Fourth Quarter and Full Year 2021 and Announces Two Additional Acquisitions

BANNOCKBURN, Ill., Feb. 23, 2022 (GLOBE NEWSWIRE) — Option Care Health, Inc. (the “Company” or “Option Care Health”) (Nasdaq: OPCH), the nation’s largest independent provider of home and alternate site infusion services, announced today financial results for the fourth quarter and full year ended December 31, 2021.

The Company also announced that it acquired Wasatch Infusion LLC (“Wasatch”), an infusion center operator based in Salt Lake City, Utah, in December and has also entered into a definitive agreement to acquire Specialty Pharmacy Nursing Network, Inc. (“SPNN”), which it expects to complete in 2022.

Fourth Quarter 2021 Financial Highlights

  • Net revenue of $927.2 million, up 15.2% compared to $804.7 million in the fourth quarter of 2020
  • Gross profit of $212.2 million, or 22.9% of revenue, up 15.5% compared to $183.8 million, or 22.8% of revenue, in the fourth quarter of 2020
  • Net income of $75.5 million, or $0.42 earnings per share inclusive of a one-time benefit from the elimination of the Company’s valuation allowance on deferred tax assets of $30.4 million or $0.17 per share, compared to net income of $17.8 million, or $0.10 earnings per share, in the fourth quarter of 2020
  • Adjusted EBITDA of $86.8 million, up 28.3% compared to $67.7 million in the fourth quarter of 2020
  • Cash flow from operations of $65.3 million, and cash balances of $119.4 million at the end of the fourth quarter
  • Acquired Infinity Infusion Nursing, LLC and Wasatch for $50.0 million and $17.8 million, respectively, financed through cash balances on hand

Full Year 2021 Financial Highlights

  • Net revenue of $3,438.6 million up 13.4% compared to $3,032.6 million in the full year 2020
  • Gross profit of $779.6 million, or 22.7% of revenue, up 14.2% compared to $682.3 million, or 22.5% of revenue, in full year 2020
  • Net income of $139.9 million, or $0.78 earnings per share, compared to net loss of $8.1 million, or $0.04 loss per share, in full year 2020
  • Adjusted EBITDA of $289.8 million, up 30.7% compared to $221.7 million in full year 2020
  • Cash flow from operations of $208.6 million, up 63.7% compared to $127.4 million in full year 2020

John C. Rademacher, Chief Executive Officer, commented, “The entire Option Care Health team continues to execute in an ongoing challenging environment. With the patient at the center of everything we do, Option Care Health served over a quarter of a million patients in 2021 despite the ongoing pandemic situation. We are proud of the results we have generated as well as the many investments we continue to make to drive future growth.”

Full Year 2022 Financial Guidance

For the full year 2022, Option Care Health expects to deliver the following financial results:

  • Net revenue of $3.65 billion to $3.85 billion
  • Adjusted EBITDA of $310 million to $330 million
  • Cash flow from operations of at least $230 million

The financial expectations do not include any impact from the acquisition of SPNN as it has not yet been completed.

Conference Call

The conference call can be accessed by dialing (866) 360-3136 for U.S. participants or (602) 563-8603 for international participants, and referencing conference ID 7156207; or via a live audio webcast that will be available online at investors.optioncarehealth.com. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.

About Option Care Health

Option Care Health is the nation’s largest independent provider of home and alternate site infusion services. With over 7,000 teammates, including approximately 4,300 clinicians, we work compassionately to elevate standards of care for patients with acute and chronic conditions in all 50 states. Through our clinical leadership, expertise and national scale, Option Care Health is reimagining the infusion care experience for patients, customers and teammates. To learn more, please visit our website at OptionCareHealth.com.

Investor Contacts

Mike Shapiro Bob East, Asher Dewhurst, Jordan Kohnstam
Chief Financial Officer Westwicke
T: (312) 940-2538 T: (413) 213-0500
mike.shapiro@optioncare.com  optioncarehealth@westwicke.com 

Forward-Looking Statements – Safe Harbor

This press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “believe,” “project,” “estimate,” “expect,” “may,” “should,” “will” and similar references to future periods. Examples of forward-looking statements include, among others, statements we may make regarding future revenues, future earnings, regulatory developments, market developments, new products and growth strategies, integration activities and the effects of any of the foregoing on our future results of operations or financial conditions.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) changes in laws and regulations applicable to our business model; (ii) changes in market conditions and receptivity to our services and offerings; (iii) results of litigation; and (iv) the loss of one or more key payers. For a detailed discussion of the risk factors that could affect our actual results, please refer to the risk factors identified in our SEC reports as filed with the SEC.

Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Note Regarding Use of Non-GAAP Financial Measures

In addition to reporting financial information in accordance with generally accepted accounting principles (GAAP), the Company is also reporting Adjusted EBITDA, which is a non-GAAP financial measure. Adjusted EBITDA is not a measurement of financial performance under GAAP and should not be used in isolation or as a substitute or alternative to net income, operating income or any other performance measure derived in accordance with GAAP, or as a substitute or alternative to cash flow from operating activities or a measure of the Company’s liquidity. In addition, the Company’s definition of Adjusted EBITDA may not be comparable to similarly titled non-GAAP financial measures reported by other companies. Adjusted EBITDA, as defined by the Company, represents net income before net interest expense, income tax expense, depreciation and amortization, stock-based compensation expense, and restructuring, integration and other expenses. As part of restructuring, integration and other expenses, the Company may incur significant charges such as the write down of certain long−lived assets, temporary redundant expenses, professional fees, potential retention and severance costs and potential accelerated payments or termination costs for certain of its contractual obligations. Management believes that Adjusted EBITDA provides useful supplemental information regarding the performance of Option Care Health’s business operations and facilitates comparisons to the Company’s historical operating results. We have not reconciled Adjusted EBITDA guidance to net income as creation of this reconciliation would not be practicable due to the uncertainty regarding, and potential variability of, material reconciling items. For a full reconciliation of Adjusted EBITDA to the most comparable GAAP financial measure, please see the attachment to this earnings release.

  Schedule 1

OPTION CARE HEALTH, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(IN THOUSANDS)

 

  December 31,
    2021     2020
ASSETS      
CURRENT ASSETS:      
Cash and cash equivalents $ 119,423   $ 99,265
Accounts receivable, net   338,242     328,340
Inventories   183,095     158,601
Prepaid expenses and other current assets   69,496     70,806
Total current assets   710,256     657,012
       
NONCURRENT ASSETS:      
Property and equipment, net   111,535     121,149
Intangible assets, net   21,433     23,429
Referral sources   344,587     327,623
Goodwill   1,477,564     1,428,610
Other noncurrent assets   125,543     89,616
Total noncurrent assets   2,080,662     1,990,427
TOTAL ASSETS $ 2,790,918   $ 2,647,439
       
LIABILITIES AND STOCKHOLDERS’ EQUITY      
CURRENT LIABILITIES:      
Accounts payable $ 279,246   $ 282,913
Other current liabilities   180,449     151,110
Total current liabilities   459,695     434,023
       
NONCURRENT LIABILITIES:      
Long-term debt, net of discount, deferred financing costs and current portion   1,059,900     1,115,103
Other noncurrent liabilities   95,437     82,589
Total noncurrent liabilities   1,155,337     1,197,692
Total liabilities   1,615,032     1,631,715
       
STOCKHOLDERS’ EQUITY   1,175,886     1,015,724
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $ 2,790,918   $ 2,647,439
           

Schedule 2

OPTION CARE HEALTH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS
(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)

 

  Three Months Ended
December 31,
  Year Ended
December 31,
    2021       2020       2021       2020  
NET REVENUE $ 927,194     $ 804,713     $ 3,438,640     $ 3,032,610  
COST OF REVENUE   714,997       620,951       2,659,034       2,350,346  
GROSS PROFIT   212,197       183,762       779,606       682,264  
               
OPERATING COSTS AND EXPENSES:              
Selling, general and administrative expenses   136,777       123,001       525,707       500,199  
Depreciation and amortization expense   14,648       16,418       63,058       71,310  
Total operating expenses   151,425       139,419       588,765       571,509  
OPERATING INCOME   60,772       44,343       190,841       110,755  
               
OTHER INCOME (EXPENSE):              
Interest expense, net   (14,286 )     (23,668 )     (67,003 )     (107,770 )
Other, net   481       (2,270 )     (7,344 )     (8,228 )
Total other expense   (13,805 )     (25,938 )     (74,347 )     (115,998 )
               
INCOME (LOSS) BEFORE INCOME TAXES   46,967       18,405       116,494       (5,243 )
               
INCOME TAX (BENEFIT) EXPENSE   (28,500 )     566       (23,404 )     2,833  
NET INCOME (LOSS) $ 75,467     $ 17,839     $ 139,898     $ (8,076 )
               
Earnings (loss) per share, basic $ 0.42     $ 0.10     $ 0.78     $ (0.04 )
Earnings (loss) per share, diluted $ 0.41     $ 0.10     $ 0.77     $ (0.04 )
                               

Schedule 3

OPTION CARE HEALTH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(IN THOUSANDS)

 

  Year Ended
December 31,
  2021     2020  
CASH FLOWS FROM OPERATING ACTIVITIES:      
Net income (loss) 139,898     (8,076 )
Adjustments to reconcile net income (loss) to net cash provided by operations:      
Depreciation and amortization expense 68,804     77,896  
Paid-in-kind interest capitalized as principal     7,525  
Other non-cash adjustments 11,237     42,917  
Changes in operating assets and liabilities:      
Accounts receivable, net (4,273 )   (3,924 )
Inventories (22,700 )   (42,725 )
Accounts payable (10,381 )   59,215  
Other 25,984     (5,436 )
Net cash provided by operating activities 208,569     127,392  
       
CASH FLOWS FROM INVESTING ACTIVITIES:      
Acquisition of property and equipment (25,632 )   (26,875 )
Other investing cash flows     541  
Business acquisitions, net of cash acquired (85,909 )    
Net cash used in investing activities (111,541 )   (26,334 )
       
CASH FLOWS FROM FINANCING ACTIVITIES:      
Proceeds from debt 855,136      
Retirement of debt obligations (910,345 )   (174,000 )
Net proceeds from issuance of common stock     118,934  
Deferred financing costs (10,339 )   (149 )
Other financing cash flows (11,322 )   (13,634 )
Net cash (used in) financing activities (76,870 )   (68,849 )
NET INCREASE IN CASH AND CASH EQUIVALENTS 20,158     32,209  
Cash and cash equivalents – beginning of the period 99,265     67,056  
CASH AND CASH EQUIVALENTS – END OF PERIOD 119,423     99,265  
           

Schedule 4

OPTION CARE HEALTH, INC.
QUARTERLY RECONCILIATION BETWEEN GAAP AND NON-GAAP MEASURES
(IN THOUSANDS)
(UNAUDITED)

 

  Three Months Ended 
 December 31,
  Year Ended
December 31,
    2021       2020     2021       2020  
Consolidated net income (loss) $ 75,467     $ 17,839   $ 139,898     $ (8,076 )
Interest expense, net   14,286       23,668     67,003       107,770  
Income tax (benefit) expense   (28,500 )     566     (23,404 )     2,833  
Depreciation and amortization expense   15,984       17,842     68,804       77,896  
Consolidated EBITDA   77,237       59,915     252,301       180,423  
               
EBITDA adjustments              
Stock-based incentive compensation   3,329       332     9,575       2,920  
Loss on extinguishment of debt   984       3,196     13,387       11,545  
Restructuring, acquisition, integration and other   5,200       4,208     14,543       26,788  
Consolidated adjusted EBITDA $ 86,750     $ 67,651   $ 289,806     $ 221,676  
                             

 

Staff

Recent Posts

HeartBeam to Attend JP Morgan 2025 Annual Healthcare Conference

HeartBeam system was recently cleared by US Food and Drug Administration (FDA) for comprehensive arrhythmia…

11 minutes ago

Glaukos Submits New Drug Application to U.S. FDA for Epioxa™

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused…

12 minutes ago

The National Children’s Cancer Society Awarded $1,000 Grant From Kars4Kids

This generous grant will directly benefit the NCCS's Beyond the Cure Ambassador Scholarship Program, which…

15 minutes ago

Honeycomb Clinic Positions for Public Offering

Medical Co-working space challenges broken healthcare system. HOUSTON, TEXAS / ACCESSWIRE / December 23, 2024…

15 minutes ago

Ensysce Biosciences Regains Full Compliance with Nasdaq

SAN DIEGO, CALIFORNIA / ACCESSWIRE / December 23, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce"…

15 minutes ago

Telomir Pharmaceuticals Confirms Copper Binding Capabilities of Telomir-1 and Expands Pipeline Into Wilson’s Disease

MIAMI, FL / ACCESSWIRE / December 23, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or the…

15 minutes ago